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Abstract
Objective. Necrotizing and crescentic GN usually presents with rapidly declining renal function, often in
association with multisystem autoimmune disease, with a poor outcome if left untreated. We aimed to
describe the features of patients who have presented with these histopathological findings but minimal
disturbance of renal function.
Methods. We conducted a retrospective review (19952011) of all adult patients with native renal bi-
opsyproven necrotizing or crescentic GN and normal serum creatinine (<120mmol/l) at our centre.
Results. Thirty-eight patients were identified. The median creatinine at presentation was 84 mmol/l and the
median proportion of glomeruli affected by necrosis or crescents was 32%. Clinicopathological diagnoses
were ANCA-associated GN (74%), LN (18%), anti-GBM disease (5%) and HScP (3%). Only 18% of cases
had pre-existing diagnoses of underlying multisystem autoimmune disease, although the majority (89%)
had extra-renal manifestations accompanying the renal diagnosis. All patients received immunosuppres-
sion and most had good long-term renal outcomes (median duration of follow-up 50 months), although
two progressed to end-stage renal disease within 3 years. We estimate that renal biopsy had an important
influence on treatment decisions in 82% of cases.
Conclusion. Necrotizing and crescentic GN may present in patients with no or only minor disturbance of
renal function. This often occurs in patients with underlying systemic autoimmune disease; early referral
for biopsy may affect management and improve long-term outcomes in these cases.
Key words: renal, histopathology, vasculitis, anti-neutrophil cytoplasm antibody, systemic lupus erythematosus,
Goodpasture’s syndrome, granulomatosis with polyangiitis, microscopic polyangiitis.
Rheumatology key messages
. Crescentic GN, including 550% crescents, may infrequently present with minimal disturbance of renal function.
. Early detection and investigation of urinary abnormalities in patients with multisystem autoimmune disease may
improve long-term outcomes.
. Renal biopsy may significantly influence treatment decisions in patients with multisystem autoimmune disease
presenting with urinary abnormalities.
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Introduction
Crescentic GN, recognized as the most severe form of
glomerular inflammation, describes the histopathological
finding of extra-capillary cells, both proliferating parietal
epithelial cells and infiltrating leucocytes, and plasma pro-
teins within Bowman’s space that is often associated with
necrosis and fragmentation of the underlying glomerular
tuft and periglomerular inflammation [1]. Classically it has
been categorized based on the pattern of immunoglobulin
deposition within the diseased glomerulus [2]: type I with
linear IgG deposition, as seen in anti-GBM disease; type II
with immune-complex deposition, seen in LN, cryoglobu-
linaemia and HScP; and type III with minimal or no im-
munoglobulin deposition (i.e. pauci-immune), associated
with circulating ANCA in 8090% of cases. It may occur in
isolation as a renal-limited phenomenon, although more
frequently it develops as a feature of multisystem autoim-
mune or rheumatic diseases [3].
The usual clinical correlate of glomerular necrosis and
crescent formation is rapidly progressive GN (RPGN)
[1, 2], i.e. an abrupt decline in renal function that occurs
over days to weeks, in association with abnormal urinary
findings of haematuria and proteinuria. Historical cohorts
suggest that if left untreated, necrotizing and crescentic
GN has an invariably poor outcome, with the majority of
patients progressing to end-stage renal disease (ESRD) or
death within months [4]. Immunosuppressive therapy has
improved renal and patient survival; however, early detec-
tion and instigation of appropriate therapy is essential to
prevent irreversible kidney damage and poor long-term
outcomes [5].
We have observed, however, a small number of patients
who have presented with preserved biochemical renal
function despite demonstrating histopathological features
of severe GN on renal biopsy. The aim of this study was to
highlight the occurrence of these cases and to define their
clinical characteristics and outcomes at our centre. For
the purposes of this study we have included all cases
with glomerular necrosis or crescents, regardless of the
number or proportion of glomeruli involved, as we wanted
to reflect the practical management of patients with these
renal biopsy findings. Similarly we used a threshold serum
creatinine of <120mmol/l, regardless of the glomerular fil-
tration rate (GFR), in order to identify those cases that
were at risk of delayed diagnosis or misdiagnosis, since
they did not present with the typical syndrome of RPGN.
In addition, the most commonly used formula used to es-
timate GFR is less reliable in patients with normal or near-
normal renal function, and is not validated in the context of
the acute kidney injury that is usually observed with cres-
centic GN [6, 7].
Methods
We retrospectively identified cases using the central renal
pathology database at the Imperial College Renal and
Transplant Centre, based at the Imperial College
Healthcare NHS Trust, a large tertiary referral centre for
nephrology that provides care to a local population of
approximately 2 million in West London, UK. In accord-
ance with the UK National Health Service Research Ethics
Committee guidelines, ethics approval was not required
because this work comprised retrospective data and all
treatment decisions were made prior to our evaluation.
We included all adult patients with a coded diagnosis of
necrotizing or crescentic GN on their first native renal
biopsy between 1995 and 2011, for whom complete
biopsy reports and at least 1 year follow-up were avail-
able. We excluded repeat native biopsies, paediatric
cases and transplant biopsies from analysis. We included
all patients with these coded diagnoses, regardless of the
number or proportion of glomeruli affected, as we wanted
to reflect real-world management of these biopsy findings
in clinical practice. Original biopsy reports were reviewed
by an experienced renal histopathologist (H.T.C.) to con-
firm suitability for inclusion in the study. A crescent was
defined as two or more layers of proliferating cells in
Bowman’s space. A normal glomerulus was defined by
the absence of necrosis, crescent formation, endocapil-
lary proliferation and segmental or global glomerulo-
sclerosis. Glomeruli with minor mesangial or ischaemic
changes only were included in this category.
To identify those cases with preserved renal function,
we used a threshold of serum creatinine <120mmol/l, the
upper reference limit in our biochemistry laboratory, at the
time of this diagnostic biopsy. We then reviewed case
notes and laboratory records for these cases to obtain
baseline demographic, clinical and biochemical data.
We collected details of treatment and clinical outcomes
(including renal function, proteinuria, dialysis status, in-
flammatory markers, autoimmune serology and mortality)
at 1, 3 and 5 years and at the last follow-up.
Comparison data for the subset of patients with ANCA-
associated vasculitis (AAV) in this cohort were obtained
from a previously collected dataset that included 82 pa-
tients with renal biopsyproven AAV at our centre over a
similar timeframe [8]. Graphs were constructed and stat-
istical analyses were performed using GraphPad Prism
5.0 (GraphPad Software, La Jolla, CA, USA).
Results
Case identification and baseline features
From a total of 3984 biopsy cases, we identified 258 with
necrotizing or crescentic GN, of which 38 cases (14.7%)
met our inclusion criteria of serum creatinine <120mmol/l
at presentation. Baseline patient demographics are
summarized in Table 1. The median age was 57 years
(range 1778). About 68% of patients were female and
the ethnicities of the cohort were in keeping with our
local population.
Histopathology
Most biopsies were diagnostically adequate, containing a
median number of 14 glomeruli (range 433). Only seven
biopsies (18%) had fewer than 10 glomeruli. Key histo-
pathological findings for the entire cohort and according
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to immuno- and clinicopathological diagnosis are
summarized in Table 2.
For the entire cohort, the median proportion of glomeruli
affected by necrosis or crescents was 32% (range 5100).
Eight per cent of the cases were affected by segmental
necrosis alone, although the majority (92%) had both ne-
crosis and crescent formation. In 26% of biopsies,550%
of glomeruli were affected by necrosis or crescents. In all
but one case, crescents were cellular or fibrocellular, sug-
gesting acute pathology.
The median proportion of normal glomeruli was 51%
(range 092). Forty-two per cent of biopsies had <50%
normal glomeruli. Tubular atrophy ranged from 0% to
40% (median 10%). Overt necrotizing arteritis was re-
ported in three cases (8%).
Table 3 summarizes the proportion of biopsies in our
cohort as stratified according to the recently described
histopathological classification system for ANCA-asso-
ciated GN (AAGN) proposed by Berden et al. [9].
Clinical and laboratory features at presentation
The median creatinine at presentation was 84 mmol/l
(range 52115) and the median estimated GFR (eGFR)
was 71 ml/min (range 50>90). The majority of cases
(79%) had an eGFR >60 ml/min.
Other biochemical features at presentation are summar-
ized in Table 1. All patients had microscopic haematuria.
All but one had detectable proteinuria [median urinary
protein:creatinine ratio (uPCR) 132 mg/mmol (range
01700)], although in 26% this was low grade (uPCR
<100 mg/mmol). Median serum albumin was 29 g/l
(range 1040). Notably, systemic inflammatory responses
were generally low [median CRP 17 mg/l (range 2278)].
Seven patients had pre-existing diagnoses of multisys-
tem autoimmune disease associated with GN (four SLE
and three AAV). In this group of patients, the median dur-
ation of illness prior to diagnosis of renal disease was 3
years (range 120). The majority of patients (89%) had
extrarenal manifestations of a pre-existing or de novo
underlying multisystem disease at the time of renal diag-
nosis. These extrarenal manifestations are summarized in
Fig. 1A.
The most common final clinicopathological diagnosis
(Table 1) was pauci-immune GN secondary to systemic
AAV (74%), of which 64% were anti-proteinase 3 (PR3)
antibody positive, 29% were anti-MPO antibody positive
and 7% were ANCA negative. The remaining patients had
SLE (seven cases), anti-GBM disease (two cases) and IgA
nephropathy associated with HScP (one case). The pro-
portion of glomeruli affected by necrosis or crescent for-
mation according to clinicopathological diagnosis is
summarized in Table 2.
Treatment
All patients were treated with immunosuppression in ac-
cordance with local practice at the time of diagnosis
TABLE 1 Demographics, clinicopathological diagnoses and biochemical parameters at presentation and
after 1 year for the entire cohort
Variable Value
Demographics
Gender, % female 68
Age, median (range), years 57 (1778)
Ethnicity, n (%)
Caucasian 24 (63)
Indo-Asian 5 (13)
Afro-Caribbean 5 (13)
Unknown 4 (11)
Clinicopathological diagnoses
AAGN, n (%) 28 (74)
Anti-PR3 antibody positive, n (% of AAV) 18 (64)
Anti-MPO antibody positive, n (% of AAV) 8 (29)
ANCA negative, n (% of AAV) 2 (7)
SLE 7 (18)
Anti-GBM disease 2 (5)
HScP 1 (3)
Biochemistry, median (range) At presentation At 1 year
Creatinine, mmol/l 84 (52115) 82 (52147)
eGFR, ml/min 71 (50132) 75 (33130)
uPCR, mg/mmol 132 (01700) 23 (0274)
Albumin, g/l 29 (1040) 38 (3046)
Serum CRP, mg/l 17 (2278) 3 (038)
AAGN: ANCA-associated GN; AAV: ANCA-associated vasculitis; eGFR: estimated glomerular filtration rate;
uPCR: urinary protein:creatinine ratio.
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(Fig. 1B). The most commonly used regimen was a com-
bination of CS (received by 97% of cases) and either oral
or i.v. CYC (68%). In 2006 we introduced rituximab as a
steroid- and CYC-sparing agent in LN and AAV [10, 11],
accounting for the high proportion of patients who also
received this agent (50%). One patient received abatacept
as part of a phase III clinical study (NCT00482066).
Maintenance immunosuppressive agents included AZA
(53%), MMF (34%) and MTX (5%). Three patients did
not receive maintenance immunosuppression (anti-GBM
disease and HScP) since they were not deemed to be at
significant risk of relapsing disease. Two patients (both
cases of anti-GBM disease) received plasma exchange
in addition to medical therapy at the time of diagnosis.
Outcomes
The median duration of follow-up was 50 months (range
2181). Biochemical outcomes at 1 year are summarized
in Table 1. The majority of patients had stable renal func-
tion after 1 year (median serum creatinine 82 mmol/l,
median eGFR 75 ml/min; censored for death and ESRF)
and beyond (Fig. 2A). Four patients died during follow-up
(at 2, 15, 95 and 122 months; causes of death unknown)
and two patients progressed to ESRD (at 21 and 39
months) both secondary to LN (Fig. 2B). In the AAV
cohort, dialysis-free survival was significantly better in
patients who presented with serum creatinine
<120mmol/l compared with those with serum creatinine
>120mmol/l over the same time period (P= 0.0001, log-
rank test; Fig. 2B).
Treatment decisions
We retrospectively reviewed the impact that renal biopsy
results had on clinical decision making. In 37 of the 38
cases (97%), the renal biopsy was the sole means of
tissue diagnosis (one patient previously had a nasal
biopsy consistent with AAV). In the 31 cases (82%) who
did not have extrarenal disease manifestations already
requiring cytotoxic or biologic therapy—specifically,
severe lung or neurological involvement—we felt that the
results of the renal biopsy significantly influenced treat-
ment decisions with regard to the choice, augmentation
or duration of immunosuppressive therapy.
Discussion
This is the largest case series of patients with biopsy-
proven severe renal pathology who presented with min-
imal disturbance of biochemical renal function and the first
series to report this finding in association with AAV. In
most cases, patients had extrarenal manifestations of a
multisystem autoimmune disease that facilitated early de-
tection of asymptomatic GN, and our observations sug-
gest that this may have improved long-term outcomes.
The most common clinicopathological diagnosis in our
cohort was pauci-immune GN secondary to AAV. It has
long been recognized that renal involvement is associated
with poorer outcomes in AAV, with several studies report-
ing that renal impairment at presentation is a strong
TABLE 2 Histopathological features of the index biopsy for the entire cohort and according to immuno- and clinico-
pathological diagnosis
Entire
cohort
Type III:
pauci-immune
Type II: immune
complex (IC)
Type I:
linear IgG
Diagnosis All AAGN SLE HScP GBM
Cases, n 38 28 7 1 2
Necrosis and crescents, median (range), % 32 (4100) 32 (4100) 17 (850) 50 36 (2647)
Crescents, median (range), % 21 (0100) 21 (0100) 16 (871) 50 32 (1747)
Obsolete glomeruli, median (range), % 4 (033) 4 (033) 0 (025) 0 9 (810)
Normal glomeruli, median (range), % 51 (092) 53 (083) 25 (092) 50 52 (4361)
Tubular atrophy, median (range), % 10 (040) 10 (040) 5 (040) 10 10 (515)
The highest proportion of crescents was seen in type I disease, followed by type III and type II disease, similar to the ranking
reported in the series where patients presented with rapidly progressive crescentic glomerulonephritis [1]. AAGN: ANCA-
associated GN.
TABLE 3 Recently proposed histopathological classifica-
tion system for ANCA-associated GN applied to our
cohort
Class
ANCA-associated
GN (n=28), %
Entire cohort
(n=38), %
Focal 57 53
Crescentic 14 18
Mixed 29 29
Sclerotic 0 0
The majority of cases had focal class disease (i.e. 550%
normal glomeruli), although a significant proportion had cres-
centic class (i.e. 550% crescentic glomeruli) or mixed class
(i.e. 450% normal glomeruli, without predominance of cres-
cents or global sclerosis) disease. No patients in this cohort
had sclerotic class disease (i.e. 550% globally sclerosed
glomeruli). While not validated for patients with other
causes of crescentic GN, application of this classification
system to our entire cohort revealed a similar distribution
of histopathological classes.
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predictor of progression to ESRD and death [1215]. The
presence of proteinuria has also been associated with
mortality in microscopic polyangiitis [16]. It would there-
fore seem logical to conclude that early detection and
treatment of renal disease should improve patient out-
comes, and observational data suggest that this may be
the case. Holle et al. [17], for example, compared out-
comes in three cohorts of patients (a total of 445 cases)
with granulomatosis with polyangiitis diagnosed between
1966 and 2002. They found that, over four decades, as
awareness of granulomatosis with polyangiitis increased
and diagnostic testing improved, there was a decrease in
the lag time between onset of first symptoms and diag-
nosis and that this was associated with lower rates of
ESRD and mortality (with effects of improved treatment
regimens and monitoring no doubt also contributing).
However, only 50% of patients in these cohorts had
renal involvement at presentation, and the nature of their
renal disease was not defined. A similar, but smaller study
of 181 patients with biopsy-proven AAGN diagnosed over
a 30 year time period had similar findings—between 1979
and 2009, there was a decrease in serum creatinine and
active lesions on kidney biopsy at the time of diagnosis,
and this was associated with improved patient and renal
survival [18].
No controlled studies have assessed the benefit of in-
tense immunosuppressive treatment specifically in pa-
tients with early renal disease and preserved renal
FIG. 2 Long-term renal outcomes
(A) Long-term renal function during the 60 month follow-up, censored for death and end-stage renal disease. Reported as
median (interquartile range). (B) Dialysis-free survival during the 60 month follow-up for the entire cohort (all sCr <120,
n= 38; shown in solid black). AAV cases only from this cohort (AAV sCr <120, n= 28; dotted plot) had significantly better
rates of dialysis-free survival compared with AAV cases with serum creatinine >120 mmol/l at presentation (AAV sCr
>120, n= 82; grey plot) over the same time period (P= 0.0001, log-rank test). AAV: ANCA-associated vasculitis; eGFR:
estimated glomerular filtration rate; sCR: serum creatinine.
FIG. 1 Extrarenal manifestations and immunosuppressive treatments used in this cohort
(A) Extra-renal manifestations at the time of renal diagnosis. (B) Agents used for induction and maintenance immuno-
suppression. ABT: abatacept; Haem: haematological; MSK: musculoskeletal; Neuro: neurological; PEX, plasma ex-
change; RTX: rituximab.
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function, since the majority of trials, including those of the
European Vasculitis Society, have enrolled patients with
severe renal dysfunction. Only the Nonrenal Wegener’s
Granulomatosis Treated Alternatively with Methotrexate
(NORAM) trial [19] excluded patients with creatinine
>150mmol, and based on its findings, MTX and gluco-
corticoid therapy may be considered as first-line therapy
for European League Against Rheumatism (EULAR) early
systemic disease [20, 21]. However, the NORAM study
excluded patients with significant proteinuria (uPCR
>100 mg/mmol) or urinary red cell casts, a surrogate
that is highly suggestive of severe GN, and thus its find-
ings are not strictly applicable to our cohort with biopsy-
proven renal disease.
Consensus opinion at our centre, based on historical
series and experience of delayed referral, is that these
patients are at significant risk of progression to fulminant
RPGN or, alternatively, more indolent renal disease that
may result in progressive glomerulosclerosis, interstitial
fibrosis and tubular atrophy, particularly in patients who
are anti-MPO antibody positive [22]. We therefore advo-
cate more potent immunosuppressive therapy, as recom-
mended for EULAR generalized stage disease, unless
contraindications are present. While uncontrolled, the
data reported here suggest that such treatment results
in excellent long-term outcomes and are consistent with
previous reports that the use of cytotoxic therapy (as
opposed to CS alone) is associated with lower mortality
in patients with AAV [12, 16].
We expect that future controlled studies will better define
which treatments are most appropriate in this type of pa-
tient. Indeed, Berden et al. [9] recently proposed a histo-
pathological classification for AAGN to enable more
accurate prognostication and to facilitate stratification in
clinical trials. This system describes four classes of dis-
ease: crescentic, focal, sclerotic and mixed. The first
three categories are based on the predominance of cres-
centic, normal and globally sclerotic glomeruli in the biopsy
specimen, respectively, while in the mixed disease class,
none of these features is predominant. Of our cohort, 61%
had focal class disease, which predicts the best renal prog-
nosis. However, 14% had crescentic class disease and
29% mixed, for which predicted renal outcomes are re-
portedly worse (6080% renal survival at 60 months),
suggesting that our rationale for immunosuppression in
this cohort was appropriate. Several validation studies of
this classification system have been published, suggesting
that it can reliably predict renal outcome in those with focal
and sclerotic class disease, whereas crescentic and mixed
class disease have variable outcomes compared with the
original cohort [23]. A large international validation study is
currently under way.
It could be argued that renal biopsy is unnecessary in
these cases and that a diagnosis of AAGN can be
assumed in patients with AAV demonstrating urinary
abnormalities. Although not the subject of this study, we
have identified several patients with AAV who did not have
evidence of AAGN on renal biopsy; alternative pathologies
included thin basement lesion, para-infectious GN and
drug-induced tubulointerstitial nephritis, for which treat-
ment significantly differs [24, 25]. Of note, Mahr et al.
[26] recently reported an ANCA seroprevalence of
almost 20% in a prospective series of patients with bac-
terial endocarditis, which can often mimic the clinical
presentation of AAV, including the features of GN. In
endocarditis, however, renal biopsy is more likely to
reveal immune-complex para-infectious features rather
than pauci-immune necrotizing GN, highlighting the utility
of securing histology in these cases. We have previously
reported on the risks of overreliance on serological testing
in AAV [27], and we therefore propose that tissue diagno-
sis with renal biopsy should remain the gold standard for
diagnosis when urinary abnormalities are present in these
patients.
Seven patients (18%) in our cohort had LN. There are
isolated case reports of crescentic LN presenting with
normal renal function in the literature [28]; however, the
finding of crescents is usually associated with significant
abnormalities of renal function and poor outcome in larger
series [29, 30], although these studies included only pa-
tients with >50% of glomeruli affected by crescent forma-
tion. That two of seven cases in our cohort progressed to
end-stage renal failure within 3 years, however, high-
lights the important observation that patients with <50%
crescentic glomeruli still have significant renal risk, des-
pite having preserved function at presentation and receiv-
ing aggressive treatment.
Two cases of anti-GBM disease were detected in our
cohort. This is widely recognized as the most aggressive
form of GN, such that presentation with normal renal bio-
chemistry is rare, though previously reported in small case
series [31, 32]. Our data suggest that with appropriate
treatment, including plasma exchange, these patients
have a good renal prognosis.
Our study has obvious limitations: it is retrospective,
uncontrolled, spans a 15 year time period and it includes
a cohort of patients who have received somewhat hetero-
geneous treatment. However, this single-centre experi-
ence, where all patients were treated with potent, if
varied, immunosuppressive regimens, illustrates several
important practice points: (i) necrotizing and crescentic
GN may present with preserved renal function and mild
urinary abnormalities rather than the expected pattern of
RPGN; (ii) this often occurs in patients with underlying
multisystem disease, so non-nephrologists should be
alert to the possibility of severe renal pathology, and urin-
alysis should be performed regularly in these patients; (iii)
we found that renal biopsy findings may significantly influ-
ence treatment decisions in these patients and believe
this remains the diagnostic gold standard when urinary
abnormalities are present and (iv) with immunosuppres-
sive treatment, the majority of these patients have a
good renal prognosis, although a small number are at
risk of progressing to ESRD.
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